The latest price target for Regulus Therapeutics (NASDAQ:RGLS) was reported by Wells Fargo on May 1, 2025. The analyst firm set a price target for $9.00 expecting RGLS to rise to within 12 months (a possible 15.09% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Regulus Therapeutics (NASDAQ:RGLS) was provided by Wells Fargo, and Regulus Therapeutics downgraded their equal-weight rating.

The last upgrade for Regulus Therapeutics Inc happened on March 27, 2025 when Wells Fargo raised their price target to $6. Wells Fargo previously had an equal-weight for Regulus Therapeutics Inc.

The last downgrade for Regulus Therapeutics Inc happened on May 1, 2025 when Wells Fargo changed their price target from N/A to $9 for Regulus Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Regulus Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Regulus Therapeutics was filed on May 1, 2025 so you should expect the next rating to be made available sometime around May 1, 2026.

While ratings are subjective and will change, the latest Regulus Therapeutics (RGLS) rating was a downgraded with a price target of $0.00 to $9.00. The current price Regulus Therapeutics (RGLS) is trading at is $7.82, which is within the analyst’s predicted range.